Context Therapeutics | Investor Presentation Deck | 25 slides · page 19 of 25
The charts show dose-response curves where the proprietary antibodies (IM301, IM302) maintain high binding to CLDN6 while showing minimal off-target binding compared to the benchmark.
Pitch deck · solution · present_solution · dense density
Slide locked Sign in to view
Slide schematic 6/6
chart 3/3 legend 1/1 list 1/1 title 1/1
Components 6
line line line legend bullet headline
Tools 2
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 0
∅
No frameworks
No framework match is anchored to this slide.